Rising bedaquiline resistance: exploring potential causes and next steps
Open Access
- 19 March 2026
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (5) , 2501531
Abstract
Although the estimated incidence of multidrug-resistant (MDR)/rifampicin-resistant (RR) tuberculosis (TB) has been relatively stable in recent years, MDR/RR-TB still represents a significant public health threat, with an estimated number of 400 000 new cases in 2023 [1]. The US Food and Drug Administration granted bedaquiline (BDQ) accelerated approval in 2012, and although the label does not include recommendations for the treatment of RR-TB, BDQ is being incorporated into all guideline-recommended standard regimens for MDR/RR-TB worldwide [1, 2].Keywords
Funding Information
- Innovative Medicines Initiative (101007873)
This publication has 26 references indexed in Scilit:
- endTB-Q results in the face of rising bedaquiline resistanceThe Lancet Respiratory Medicine, 2025
- Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyThe Lancet Regional Health - Europe, 2025
- Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort studyThe Lancet Infectious Diseases, 2025
- Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosisThe Lancet Respiratory Medicine, 2023
- Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational studyThe Lancet Infectious Diseases, 2023
- Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort studyThe Lancet Microbe, 2023
- ‘Those who cannot remember the past are condemned to repeat it’: Drug-susceptibility testing for bedaquiline and delamanidInternational Journal of Infectious Diseases, 2019
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosisExpert Review of Clinical Pharmacology, 2016
- Pitfalls in the Care of Patients With TuberculosisJAMA, 1993